395 related articles for article (PubMed ID: 30862637)
1. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
2. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
3. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
[TBL] [Abstract][Full Text] [Related]
4. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
Goodwin A; Parker S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2009 Oct; (4):CD000563. PubMed ID: 19821272
[TBL] [Abstract][Full Text] [Related]
5. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
Goodwin A; Parker S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2009 Jul; (3):CD000563. PubMed ID: 19588320
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
7. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
8. Estimating the magnitude of clinical benefit of local therapy in patients with DCIS.
Hwang ES; Malek V
Breast; 2019 Nov; 48 Suppl 1():S34-S38. PubMed ID: 31839157
[TBL] [Abstract][Full Text] [Related]
9. Incidence of and treatment for ductal carcinoma in situ of the breast.
Ernster VL; Barclay J; Kerlikowske K; Grady D; Henderson C
JAMA; 1996 Mar; 275(12):913-8. PubMed ID: 8598618
[TBL] [Abstract][Full Text] [Related]
10. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
11. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
12. Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO; Smith BL; Lehman CD; Vijapura CA; Pinnamaneni N; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4459-4465. PubMed ID: 32418079
[TBL] [Abstract][Full Text] [Related]
13. A review of the management of ductal carcinoma in situ following breast conserving surgery.
Boxer MM; Delaney GP; Chua BH
Breast; 2013 Dec; 22(6):1019-25. PubMed ID: 24070852
[TBL] [Abstract][Full Text] [Related]
14. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
15. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
16. Influence of local treatment on the recurrence rate of ductal carcinoma in situ.
Warneke J; Grossklaus D; Davis J; Stea B; Bebb G; Taylor C; Hastings R; Villar H
J Am Coll Surg; 1995 Jun; 180(6):683-8. PubMed ID: 7773481
[TBL] [Abstract][Full Text] [Related]
17. Management of ductal carcinoma in situ.
Vezeridis MP; Bland KI
Surg Oncol; 1994 Dec; 3(6):309-25. PubMed ID: 7773449
[TBL] [Abstract][Full Text] [Related]
18. Treatment trends for ductal carcinoma in situ of the breast.
Winchester DP; Menck HR; Osteen RT; Kraybill W
Ann Surg Oncol; 1995 May; 2(3):207-13. PubMed ID: 7641016
[TBL] [Abstract][Full Text] [Related]
19. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
20. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
